BioNTech Buys Priority Review Voucher for $205 Million for Future Oncology Filing
Key Facts
BioNTech announced on November 10, 2026, an agreement to buy a priority review voucher from Scholar Rock for $205 million in cash, giving it a faster review path for one future drug application. In its filing with the U.S. Securities and Exchange Commission, the company said it intends to use the voucher to support an application involving one of the assets in its late-stage oncology pipeline. BioNTech did not name the asset or specify when it would submit the application. The deal remains subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino Act. According to the filing, the voucher gives the U.S. Food and Drug Administration priority review of one application and could lead to faster approval.
The FDA’s targets indicate the potential time saved during application review: the agency aims to take action on a priority review application within 6 months, compared with 10 months for a standard review. The difference between the targets is four months, but it reflects a general comparison of the agency’s review pathways, not a timeline estimate for BioNTech’s application or a guarantee of when it will be approved. The agency said the priority designation relates to its target time for taking action on an application. The voucher’s $205 million price is the cash consideration BioNTech agreed to pay Scholar Rock for this regulatory benefit. Its actual use depends on the submission of an application and its meeting review requirements.
Priority review does not shorten the clinical-trial period, according to the FDA, or change the scientific and medical standard the agency applies or the level of evidence required for approval. The agency makes the priority review determination for each application individually, and an applicant may expressly request priority under guidance for expedited programs for drugs and biologics intended to treat serious conditions. The FDA informs applicants of its priority review decision within 60 days of receiving the original application or efficacy supplement. The voucher therefore accelerates the regulatory review target for one application; it does not bypass clinical development or ease requirements to demonstrate safety and efficacy. BioNTech’s filing did not specify when it would submit the application it intends to support with the voucher.
The deal comes amid a late-stage oncology pipeline spanning several therapeutic approaches, including immunomodulators, antibody-drug conjugates and mRNA-based cancer immunotherapies. In an update issued in October 2026, BioNTech said it had 13 ongoing Phase 3 trials in its oncology pipeline. The company’s January 2026 outlook pointed to seven late-stage data readouts during the year and said the number of ongoing Phase 3 trials would reach 15 by the end of 2026. The figures place the voucher within a broader development program, but do not identify which trial or asset would benefit from the supported application. The company also did not say whether the asset in question is tied to any of its disclosed programs or an existing drug partnership.
BioNTech’s oncology development partners included Bristol Myers Squibb, Duality Biologics, Roche’s Genentech, Genmab, MediLink, OncoC4 and Pfizer. The company said the partnerships bring together complementary expertise and resources to support innovation and advance the development of its treatments. In its October update, BioNTech highlighted preliminary data from a global Phase 2 trial combining pumitamig with docetaxel to treat metastatic non-small cell lung cancer after immunochemotherapy; the data were scheduled to be presented at the European Society for Medical Oncology congress on October 25, 2026. The company said at the time that it had 13 Phase 3 trials, against its January target of 15 by year-end. BioNTech has not publicly linked these programs or the trial mentioned to the voucher it agreed to buy.
In trading, BioNTech shares, listed under the ticker BNTX, closed at $85.6 on November 13, 2026, after the agreement was announced on November 10. The closing-session data in the evidence do not include the day’s high and low prices. The deal’s regulatory impact remains tied to a future application for which the company has not disclosed the asset or filing date. The FDA’s review targets remain 6 months for priority review versus 10 months for standard review, while clinical trials and the evidence standard remain outside the scope of that time reduction.